LEGN - Legend Biotech Corp logo

Legend Biotech Corp

LEGN
Revenue grew 100% of years5Y
Compare LEGN Hold

Legend Biotech develops and manufactures cell therapies for oncology, focusing on its lead product, a CAR-T therapy for multiple myeloma. It also targets various cancers with earlier-stage CAR-T candidates and collaborates with Janssen and Novartis.

⚕️ Healthcare NASDAQ Listed 2020 $ USD
$1,000 invested 5 years ago →$356today

Score Overview

1 Year
Score
Net Growth69.14%
Net TrendGrew
Net Income Consistency—
Rev Growth23.56%
Rev TrendGrew
Revenue Consistency—
5 Years
Score6.1
Net Growth77.30%
Net Trend40%
Net Income Consistency—
Rev Growth18x
Rev TrendEvery year
Revenue Consistency—
All Time
Score
Net Growth65.61%
Net Trend33%
Net Income Consistency
Rev Growth16x
Rev Trend83%
Revenue Consistency

Explore the 2021 public Archive ranking →

Where Legend Biotech Corp has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. LEGN does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 18.90—
1 Year2025-10-22
$ 32.11-41.14%
5 Years2021-10-22
$ 53.08-64.39%
All Time2020-06-05
$ 37.00-48.92%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 1.27B-$ 91M$ 964M
2025$ 1.02B-$ 296M$ 948M
2024$ 627M-$ 177M$ 1.12B
2023$ 285M-$ 518M$ 1.30B
2022$ 117M-$ 446M$ 1.02B
2021$ 68M-$ 403M$ 882M
IPO2020$ 75M-$ 266M$ 506M
LEGN - Legend Biotech Corp logo

Legend Biotech Corp fundamental performance

Between 2020 and 2025, revenue grew from $ 75M to $ 1.02B and net income went from -$ 266M to -$ 296M. Revenue increased in every one of those 5 years; net income in 2.

Legend Biotech Corp currently holds a 5-year HDB Score of 6.1 out of 10. How the HDB Score is calculated.

Membership

Explore LEGN with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year · Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies